Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical submits IND for US clinical trials
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an In…
Sedana Medical AB (publ), Third Quarter Report 2021
Regulatory
Sedaconda (isoflurane) approved in 11 European markets
Sedana Medical’s Nomination committee appointed
Regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General…
Financial Calendar
| Year-End report 2021 | 17 February 2022 | 07:00 |
| Annual report 2021 | 07 April 2022 | 07:00 |
